CIK治疗顺铂耐药恶性胸腔积液的临床观察  

Clinical observation of cytokine-induced killer cells in treatment of cisplatin-resistant malignant pleural effusion

作　　者：朱彦博[1] 李大鹏[1] 王振欣[1] 陶敏[1] 熊峰[1] 

机构地区：[1]苏州大学附属第一医院肿瘤科,苏州215006

出　　处：《南通大学学报（医学版）》2013年第6期487-490,共4页Journal of Nantong University(Medical sciences)

摘　　要：目的 :观察自体细胞因子诱导杀伤细胞(cytokine-induced killer cells,CIK)治疗恶性胸腔积液(malignant pleural effusion,MPE)的效果。方法 :将43例顺铂耐药MPE患者随机分组,均采用中心静脉导管持续引流,胸腔积液引流彻底后,22例观察组采用胸腔内注入CIK;21例对照组采用白介素-2、金葡素、恩度等生物制剂胸腔内注入,比较两组有效率及平均需要医学处理的时间。结果:观察组胸腔积液治疗有效率为50.0%,平均需要医学处理的时间为18.0 d;对照组的有效率为19.0%,平均需要医学处理的时间为12.2 d。结论:CIK胸腔内注入治疗MPE有效率较高,安全性好,可减少需要再次医学处理的时间。Objective： To observe the effects of cytokine-induced killer cells as second line therapy for the patients with malignant pleural effusion（MPE）. Methods： The 43 cases of patients with cisplatin-resistant MPE drain the MPE with central venous catheter, they were randomized to two groups. 22 cases in the treatment group were injected into the thorax with CIK cells and 21 cases in the control group using biological agents such as interleukin-2 , staphylococcin and endostar. Compare the two groups’ efficiency and the average time needed medical treatment. Results： The efficiency of treatment group was 50.0%, the average time needed medical treatment was 18.0 days;efficiency of control group was 19.0%, the average time needed medical treatment was 12.2 days. Conclusion： CIK intrapleural treatment for patients with MPE had higher efficiency and safety, it could reduce the number of cases needed medical treatment again.

关 键 词：恶性胸腔积液 细胞因子诱导杀伤细胞 顺铂耐药 

分 类 号：R730.6[医药卫生—肿瘤]